AAD 2022: Lebrikizumab Effective in Moderate-to-Severe Atopic Dermatitis
Novel biologic may provide new therapeutic option for treatment of moderate-to-severe atopic dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.